声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。11 月 7 日,CDE 官网显示,复星万邦的司美格鲁肽注射液上市申请获得受理,据推测,本次申报适应症为 2 型糖尿病。目前,这已是第 9 款申报上市的国产司美格鲁肽。复星万邦已完成一项旨在评价其疗效和安全性的Ⅲ期临床研究。司美格鲁肽原研由诺和诺德开发。...
Source Link声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。11 月 7 日,CDE 官网显示,复星万邦的司美格鲁肽注射液上市申请获得受理,据推测,本次申报适应症为 2 型糖尿病。目前,这已是第 9 款申报上市的国产司美格鲁肽。复星万邦已完成一项旨在评价其疗效和安全性的Ⅲ期临床研究。司美格鲁肽原研由诺和诺德开发。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.